Crispr Therapeutics (CRSP) Issues Quarterly Earnings Results

Crispr Therapeutics (NASDAQ:CRSP) issued its quarterly earnings results on Thursday. The company reported ($1.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.33), Briefing.com reports. The business had revenue of $0.56 million during the quarter, compared to the consensus estimate of $2.64 million. Crispr Therapeutics had a negative return on equity of 47.32% and a negative net margin of 331.84%. The business’s quarterly revenue was down 76.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.62) earnings per share.

Shares of CRSP traded down $1.33 on Friday, reaching $36.37. 539,024 shares of the stock traded hands, compared to its average volume of 950,146. The stock has a market cap of $1.83 billion, a PE ratio of -21.27 and a beta of 3.75. Crispr Therapeutics has a 12 month low of $16.70 and a 12 month high of $73.90.

An institutional investor recently raised its position in Crispr Therapeutics stock. Bank of New York Mellon Corp increased its position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) by 42.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,104 shares of the company’s stock after purchasing an additional 9,326 shares during the period. Bank of New York Mellon Corp owned about 0.07% of Crispr Therapeutics worth $1,827,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 39.49% of the company’s stock.

CRSP has been the topic of several recent analyst reports. Chardan Capital reaffirmed a “buy” rating and issued a $72.50 price target on shares of Crispr Therapeutics in a research report on Wednesday, August 8th. BidaskClub raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 3rd. Cann reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research report on Monday, September 17th. Zacks Investment Research upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, September 12th. Finally, Guggenheim began coverage on Crispr Therapeutics in a research report on Tuesday, October 9th. They set a “neutral” rating on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $62.47.

COPYRIGHT VIOLATION WARNING: “Crispr Therapeutics (CRSP) Issues Quarterly Earnings Results” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/11/10/crispr-therapeutics-crsp-issues-quarterly-earnings-results.html.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Further Reading: Understanding each part of a balance sheet

Earnings History for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply